Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MKS Instruments (MKSI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

MKS InstrumentsTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

MKS Instruments vs Regeneron Pharmaceuticals Inc — how do they compare? MKS Instruments trades at $268.04 (market cap $17.95B), while Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.6× MKS Instruments's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.46%). Which is the better fit depends on your goals.

MKSIREGN
Market Cap
$17.95B$83.43B
Sector
TechnologyHealth
52-Week High
$444.80$852.03
52-Week Low
$110.60$555.51
Enterprise Value
$21.53B$78.14B
Dividend Yield
0.38%0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MKS Instruments

No Aura AI signal available yet.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MKS Instruments

MKS develops instruments, systems, and process control solutions for advanced manufacturing. Its technologies serve semiconductor manufacturing, electronics and packaging, photonics, and specialty industrial applications.

Read more on MKSI

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN